Evaluation of Brain Atrophy in CIS Patients on Avonex
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01592474 |
Recruitment Status :
Completed
First Posted : May 7, 2012
Last Update Posted : July 9, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is
- To examine if Avaonex can delay the development of clinically definite multiple sclerosis.
- To investigate if Avonex can delay disability progression by slowing brain atrophy.
Condition or disease |
---|
Multiple Sclerosis |
- Multiple sclerosis (MS) is a chronic inflammatory disorder characterized by focal areas of demyelination in the central nervous system (CNS). MRI findings suggest that we should look at gray matter atrophy as a marker of the disease process in MS.
- Avonex is a proven effective disease-modifying treatment, which reduces total brain and GM atrophy and should be considered first-line therapy in patients with RRMS and CIS.
- The original SET study is an open-label observational study of high risk subjects after CIS for development of CDMS that will enroll 220 patients who have started Avonex immediately after their first clinical attack in Czech Republic, and are followed with clinical and MRI examinations for 4 years at 0, 6, 12, 24, 36 and 48 months. The clinical and MRI acquisition examinations of this study are conducted in Czech Republic.
Study Type : | Observational |
Actual Enrollment : | 180 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNβ-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy) |
Study Start Date : | October 2005 |
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | June 2012 |

- Can Avonex delay development of clinically definite MS? [ Time Frame: 5 ]To examine whether Avonex can delay the development of clinically definite multiple sclerosis
- Can Avonex delay disability progression? [ Time Frame: 5 ]To investigate if Avonex can delay disability progression by slowing brain atrophy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- MRI findings must reveal at least 2 hyperintense lesions on T2-WI or FLAIR images at first clinical onset
- CSF examination should confirm oligoclonal bands (examination must be done in an internationally approved lab and the CSF taken before the treatment of attack starts)
- Age 18 - 55 years
- Effective contraception in female patients of childbearing potential
- Kurtzke EDSS ≤ 3.5 at baseline
- Willingness to accept the plan of the study and compliance with the study
- Time from the beginning of first symptoms of CIS to baseline visit should not exceed 4 months (baseline MRI and baseline visit will be organized first 28 days after last steroid administration)
- CIS attack is treated by at least 3g of methylprednisolone without taper
- In case of severe attack 1 g of cyclophosphamide does not disqualify the patient from the study if first MRI and CSF examination was done before treatment administered
- No active major organ disease especially of hepatic or thyroid origin
Exclusion Criteria:
- The clinical diagnosis of MS is definite (the second attack occurs before the baseline visit)
- Age less than 18 or more than 55
- Non-effective contraception method or pregnancy planning
- Active major organ disease, especially hepatic or endocrinologic
- Cooperation of the subject cannot be ensured
- Kurtzke EDSS higher than 3.5 at baseline

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01592474
Principal Investigator: | Robert Zivadinov, MD,PhD,FAAN | University at Buffalo |
Responsible Party: | Robert Zivadinov, MD, PhD, Director, Buffalo Neuroimaging Analysis Center, Professor, University at Buffalo |
ClinicalTrials.gov Identifier: | NCT01592474 |
Other Study ID Numbers: |
SET |
First Posted: | May 7, 2012 Key Record Dates |
Last Update Posted: | July 9, 2014 |
Last Verified: | July 2014 |
Multiple Sclerosis Avonex Brain atrophy MRI |
Interferon-beta 1a IFN Beta 1-a Clinically isolated syndrome CIS |
Multiple Sclerosis Sclerosis Atrophy Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Pathological Conditions, Anatomical |